Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Revenue of Vericel Corporation (VCEL)
Revenue in 2023 (TTM): $197.52 M
According to Vericel Corporation's latest financial reports the company's current revenue (TTM) is $197.52 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vericel Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $197.52 M | $135.58 M | $-1,832,000 | $-2,368,000 | $-3,182,000 |
| 2022 | $164.37 M | $109.79 M | $-15,622,000 | $-15,988,000 | $-16,709,000 |
| 2021 | $156.18 M | $106.03 M | $-7,578,000 | $-7,582,000 | $-7,471,000 |
| 2020 | $124.18 M | $84.23 M | $3.05 M | $3.04 M | $2.86 M |
| 2019 | $117.85 M | $80.28 M | $-9,657,000 | $-9,665,000 | $-7,909,000 |
| 2018 | $90.86 M | $58.7 M | $-3,043,000 | $-8,137,000 | $-8,137,000 |
| 2017 | $63.92 M | $33.57 M | $-15,062,000 | $-17,286,000 | $-17,286,000 |
| 2016 | $54.38 M | $26.08 M | $-16,609,000 | $-19,566,000 | $-19,566,000 |
| 2015 | $51.17 M | $24.7 M | $-16,588,000 | $-16,340,000 | $-16,340,000 |
| 2014 | $28.8 M | $11.5 M | $-23,512,000 | $-19,920,000 | $-19,920,000 |
| 2013 | $19 K | $15 K | $-20,459,000 | $-15,622,000 | $-15,622,000 |
| 2012 | $21 K | $15 K | $-33,061,000 | $-29,474,000 | $-29,474,000 |
| 2011 | $18 K | $14 K | $-37,722,000 | $-19,711,000 | $-19,668,000 |
| 2010 | $89 K | $55 K | $-17,212,000 | $-17,729,000 | $-17,729,000 |
| 2009 | $182 K | $70 K | $-15,465,000 | $-15,946,000 | $-15,946,000 |
| 2008 | $522 K | $466 K | $-20,868,000 | $-20,133,000 | $-20,133,000 |
| 2007 | $685 K | $656 K | $-19,469,000 | $-16,475,000 | $-17,594,000 |
| 2006 | $863 K | $852 K | $-17,542,000 | $-11,811,000 | $-16,475,000 |
| 2005 | $909 K | $761 K | $-12,330,000 | $-12,405,000 | $-11,811,000 |
| 2004 | $1.3 M | $1.02 M | $-10,532,000 | $-10,488,000 | $-10,488,000 |
| 2003 | $844 K | $-49,000 | $-9,594,000 | $-9,579,000 | $-9,579,000 |
| 2002 | $877 K | $675 K | $-8,155,000 | $-7,939,000 | $-7,939,000 |
| 2001 | $899 K | $886 K | $-6,477,000 | $-9,390,000 | $-5,926,000 |
| 2000 | $1.15 M | $224 K | $-9,429,000 | $-9,390,000 | $-9,390,000 |
| 1999 | $881 K | $875 K | $-13,843,000 | $-11,595,000 | $-11,028,000 |
| 1998 | $249 K | $249 K | $-17,730,000 | $ | $-17,233,000 |
| 1997 | $400 K | $900 K | $-15,200,000 | $-14,300,000 | $-14,300,000 |
| 1996 | $1.6 M | $-8,000,000 | $-10,800,000 | $-9,800,000 | $-9,900,000 |